aXichem (AXIC) Q1 2025 earnings summary

Executive summary

• Net sales for Q1 2025 reached SEK 3,387 thousand, a significant increase from SEK 808 thousand year-over-year.

• Operating loss widened to SEK -5,876 thousand from SEK -4,500 thousand compared to Q1 2024.

• Cash position improved to SEK 9,653 thousand as of March 31, 2025, up from SEK 467 thousand a year earlier.

• Major order for axiphen from Chr. Olesen in Brazil valued at SEK 7 million, with first call-off of SEK 1.5 million post-period.

• Continued positive results from efficacy studies for aXivite and aXiphen, supporting commercial expansion.

Financial highlights

• Net sales increased to SEK 3,387 thousand from SEK 808 thousand year-over-year.

• Operating profit was SEK -5,876 thousand, down from SEK -4,500 thousand in Q1 2024.

• Profit after tax was SEK -5,876 thousand, compared to SEK -5,313 thousand in Q1 2024.

• Earnings per share improved to SEK -0.10 from SEK -0.25 year-over-year.

• Cash and cash equivalents at period end were SEK 9,653 thousand, up from SEK 467 thousand.

Outlook and guidance

• Gradual increase in order intake expected in both animal feed and dietary supplements in coming years.

• Ongoing commercialization of phenylcapsaicin under aXiphen and aXivite brands in prioritized markets.

• EU Feed Additive approval for aXiphen pending completion of one final efficacy study.

• Market approvals for animal feed applications in the USA and India are prepared but not prioritized.